Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. ENGAGE did not meet its primary or secondary endpoints.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
• 2 OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease.
• 3 DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: